Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Caubet, MS; Elbast, W; Dubuc, MC; Brazier, JL
   Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolicratios to assess CYP1A2 enzyme activity
   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
   
   M.S. Caubet et al., "Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolicratios to assess CYP1A2 enzyme activity", J PHARM B, 27(1-2), 2002, pp. 261-270
2. Wu, XZ; Noda, A; Noda, H; Imamura, Y
   Side-chain metabolism of propranolol: involvement of monoamine oxidase andaldehyde reductase in the metabolism of N-desisopropylpropranolol to propranolol glycol in rat liver
   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
   
   X.Z. Wu et al., "Side-chain metabolism of propranolol: involvement of monoamine oxidase andaldehyde reductase in the metabolism of N-desisopropylpropranolol to propranolol glycol in rat liver", COMP BIOC C, 129(4), 2001, pp. 361-368
3. Gonzalez, FJ; Kimura, S
   Understanding the role of xenobiotic-metabolism in chemical carcinogenesisusing gene knockout mice
   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
   
   F.J. Gonzalez e S. Kimura, "Understanding the role of xenobiotic-metabolism in chemical carcinogenesisusing gene knockout mice", MUT RES-F M, 477(1-2), 2001, pp. 79-87
4. Desai, HD; Seabolt, J; Jann, MW
   Smoking in patients receiving psychotropic medications - A pharmacokineticperspective
   CNS DRUGS
   
   H.D. Desai et al., "Smoking in patients receiving psychotropic medications - A pharmacokineticperspective", CNS DRUGS, 15(6), 2001, pp. 469-494
5. Diliberto, JJ; DeVito, MJ; Ross, GD; Birnbaum, LS
   Subchronic exposure of [H-3]-2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) infemale B6C3F1 mice: Relationship of steady-state levels to disposition andmetabolism
   TOXICOLOGICAL SCIENCES
   
   J.J. Diliberto et al., "Subchronic exposure of [H-3]-2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) infemale B6C3F1 mice: Relationship of steady-state levels to disposition andmetabolism", TOXICOL SCI, 61(2), 2001, pp. 241-255
6. Renwick, AG; Dorne, JLCM; Walton, K
   Pathway-related factors: The potential for human data to improve the scientific basis of risk assessment
   HUMAN AND ECOLOGICAL RISK ASSESSMENT
   
   A.G. Renwick et al., "Pathway-related factors: The potential for human data to improve the scientific basis of risk assessment", HUM ECOL R, 7(1), 2001, pp. 165-180
7. Han, XM; Ou-Yang, DS; Lu, PX; Jiang, CH; Shu, Y; Chen, XP; Tan, ZR; Zhou, HH
   Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2
   PHARMACOGENETICS
   
   X.M. Han et al., "Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2", PHARMACOGEN, 11(5), 2001, pp. 429-435
8. Corchero, J; Pimprale, S; Kimura, S; Gonzalez, FJ
   Organization of the CYP1A cluster on human chromosome 15: implications forgene regulation
   PHARMACOGENETICS
   
   J. Corchero et al., "Organization of the CYP1A cluster on human chromosome 15: implications forgene regulation", PHARMACOGEN, 11(1), 2001, pp. 1-6
9. Lelouet, H; Bechtel, YC; Paintaud, G; Brientini, MP; Miguet, JP; Bechtel, PR
   Caffeine metabolism in a group, of 67 patients with primary biliary cirrhosis
   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
   
   H. Lelouet et al., "Caffeine metabolism in a group, of 67 patients with primary biliary cirrhosis", INT J CL PH, 39(1), 2001, pp. 25-32
10. Bu, HZ; Knuth, K; Magis, L; Teitelbaum, P
    High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy - V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    
    H.Z. Bu et al., "High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy - V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment", EUR J PH SC, 12(4), 2001, pp. 447-452
11. Matsunaga, N; Hattori, K; Iizasa, H; Kizu, J; Takanaka, A; Nakashima, E
    Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    N. Matsunaga et al., "Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease", BIOL PHAR B, 24(9), 2001, pp. 1037-1043
12. Skene, DJ; Papagiannidou, E; Hashemi, E; Snelling, J; Lewis, DFV; Fernandez, M; Ioannides, C
    Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices
    JOURNAL OF PINEAL RESEARCH
    
    D.J. Skene et al., "Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices", J PINEAL R, 31(4), 2001, pp. 333-342
13. Rodriguez, JB
    Pharmacogenetics in clinical pharmacology: Present and future
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    
    J.B. Rodriguez, "Pharmacogenetics in clinical pharmacology: Present and future", METH FIND E, 23(6), 2001, pp. 307-307
14. Gonzalez, FJ
    The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis
    TOXICOLOGY LETTERS
    
    F.J. Gonzalez, "The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis", TOX LETT, 120(1-3), 2001, pp. 199-208
15. Ingelman-Sundberg, M
    Genetic variability in susceptibility and response to toxicants
    TOXICOLOGY LETTERS
    
    M. Ingelman-Sundberg, "Genetic variability in susceptibility and response to toxicants", TOX LETT, 120(1-3), 2001, pp. 259-268
16. Sofowora, GG; Choo, EF; Mayo, G; Shyr, Y; Wilkinson, GR
    In vivo inhibition of human CYP1A2 activity by oltipraz
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    G.G. Sofowora et al., "In vivo inhibition of human CYP1A2 activity by oltipraz", CANC CHEMOT, 47(6), 2001, pp. 505-510
17. Koch, KM; Ricci, BM; Hedayetullah, NS; Jewell, D; Kersey, KE
    Effect of alosetron on theophylline pharmacokinetics
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    K.M. Koch et al., "Effect of alosetron on theophylline pharmacokinetics", BR J CL PH, 52(5), 2001, pp. 596-600
18. Simon, T; Becquemont, L; Hamon, B; Nouyrigat, E; Chodjania, Y; Poirier, JM; Funck-Brentano, C; Jaillon, P
    Variability of cytochrome P450 1A2 activity over time in young and elderlyhealthy volunteers
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    T. Simon et al., "Variability of cytochrome P450 1A2 activity over time in young and elderlyhealthy volunteers", BR J CL PH, 52(5), 2001, pp. 601-604
19. Wei, C; Caccavale, RJ; Kehoe, JJ; Thomas, PE; Iba, MM
    CYP1A2 is expressed along with CYP1A1 in the human lung (vol 164, pg 25, 2001)
    CANCER LETTERS
    
    C. Wei et al., "CYP1A2 is expressed along with CYP1A1 in the human lung (vol 164, pg 25, 2001)", CANCER LETT, 171(1), 2001, pp. 111
20. Wei, C; Cacavale, RJ; Kehoe, JJ; Thomas, PE; Iba, MM
    CYP1A2 is expressed along with CYP1A1 in the human lung
    CANCER LETTERS
    
    C. Wei et al., "CYP1A2 is expressed along with CYP1A1 in the human lung", CANCER LETT, 164(1), 2001, pp. 25-32
21. Walton, K; Dorne, JL; Renwick, AG
    Uncertainty factors for chemical risk assessment: interspecies differencesin the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates
    FOOD AND CHEMICAL TOXICOLOGY
    
    K. Walton et al., "Uncertainty factors for chemical risk assessment: interspecies differencesin the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates", FOOD CHEM T, 39(7), 2001, pp. 667-680
22. Dorne, JLCM; Walton, K; Renwick, AG
    Uncertainty factors for chemical risk assessment: human variability in thepharmacokinetics of CYP1A2 probe substrates
    FOOD AND CHEMICAL TOXICOLOGY
    
    J.L.C.M. Dorne et al., "Uncertainty factors for chemical risk assessment: human variability in thepharmacokinetics of CYP1A2 probe substrates", FOOD CHEM T, 39(7), 2001, pp. 681-696
23. Meyer, JM
    Individual changes in clozapine levels after smoking cessation: Results and a predictive model
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    
    J.M. Meyer, "Individual changes in clozapine levels after smoking cessation: Results and a predictive model", J CL PSYCH, 21(6), 2001, pp. 569-574
24. Schulz, TG; Thiel, R; Neubert, D; Brassil, PJ; Schulz-Utermoehl, T; Boobis, AR; Edwards, RJ
    Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY
    
    T.G. Schulz et al., "Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies", BBA-PROT ST, 1546(1), 2001, pp. 143-155
25. Ozdemir, V; Basile, VS; Masellis, M; Kennedy, JL
    Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes
    JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS
    
    V. Ozdemir et al., "Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes", J BIOCH BIO, 47(1-2), 2001, pp. 151-157
26. Eap, CB; Bondolfi, G; Zullino, D; Bryois, C; Fuciec, M; Savary, L; Jonzier-Perey, M; Baumann, P
    Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test
    THERAPEUTIC DRUG MONITORING
    
    C.B. Eap et al., "Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test", THER DRUG M, 23(3), 2001, pp. 228-231
27. Salmela, KS; Tsyrlov, IB; Lieber, CS
    Azide inhibits human cytochrome P-4502E1, 1A2, and 3A4
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
    
    K.S. Salmela et al., "Azide inhibits human cytochrome P-4502E1, 1A2, and 3A4", ALC CLIN EX, 25(2), 2001, pp. 253-260
28. Bapiro, TE; Egnell, AC; Hasler, JA; Masimirembwa, CM
    Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S
    DRUG METABOLISM AND DISPOSITION
    
    T.E. Bapiro et al., "Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S", DRUG META D, 29(1), 2001, pp. 30-35
29. Nebert, DW; Roe, AL
    Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer
    SCIENCE OF THE TOTAL ENVIRONMENT
    
    D.W. Nebert e A.L. Roe, "Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer", SCI TOTAL E, 274(1-3), 2001, pp. 93-102
30. Kappers, WA; Edwards, RJ; Murray, S; Boobis, AR
    Diazinon is activated by CYP2C19 in human liver
    TOXICOLOGY AND APPLIED PHARMACOLOGY
    
    W.A. Kappers et al., "Diazinon is activated by CYP2C19 in human liver", TOX APPL PH, 177(1), 2001, pp. 68-76
31. Bray, BJ; Rosengren, RJ
    Retinol potentiates acetaminophen-induced hepatotoxicity in the mouse: Mechanistic studies
    TOXICOLOGY AND APPLIED PHARMACOLOGY
    
    B.J. Bray e R.J. Rosengren, "Retinol potentiates acetaminophen-induced hepatotoxicity in the mouse: Mechanistic studies", TOX APPL PH, 173(3), 2001, pp. 129-136
32. Smith, AG; Clothier, B; Carthew, P; Childs, NL; Sinclair, PR; Nebert, DW; Dalton, TP
    Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
    TOXICOLOGY AND APPLIED PHARMACOLOGY
    
    A.G. Smith et al., "Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin", TOX APPL PH, 173(2), 2001, pp. 89-98
33. Vakharia, DD; Liu, N; Pause, R; Fasco, M; Bessette, E; Zhang, QY; Kaminsky, LS
    Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepatocyte cultures
    TOXICOLOGY AND APPLIED PHARMACOLOGY
    
    D.D. Vakharia et al., "Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepatocyte cultures", TOX APPL PH, 170(2), 2001, pp. 93-103
34. Janus, K; Antoszek, J; Suszycki, S
    The effect of short-term starvation or water deprivation caffeine pharmacokinetics in calves
    RESEARCH IN VETERINARY SCIENCE
    
    K. Janus et al., "The effect of short-term starvation or water deprivation caffeine pharmacokinetics in calves", RES VET SCI, 70(2), 2001, pp. 109-113
35. Sy, SKB; Tang, BK; Pastrakuljic, A; Roberts, EA; Kalow, W
    Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    S.K.B. Sy et al., "Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine", EUR J CL PH, 57(5), 2001, pp. 377-386
36. Kivisto, KT; Wang, JS; Backman, JT; Nyman, L; Taavitsainen, P; Anttila, M; Neuvonen, PJ
    Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    K.T. Kivisto et al., "Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole", EUR J CL PH, 57(1), 2001, pp. 37-42
37. Facciola, G; Hidestrand, M; von Bahr, C; Tybring, G
    Cytochrome P-450 isoforms involved in melatonin metabolism in human liver microsomes
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    G. Facciola et al., "Cytochrome P-450 isoforms involved in melatonin metabolism in human liver microsomes", EUR J CL PH, 56(12), 2001, pp. 881-888
38. Hammons, GJ; Yan-Sanders, Y; Jin, B; Blann, E; Kadlubar, FF; Lyn-Cook, BD
    Specific site methylation in the 5 '-flanking region of CYP1A2 - Interindividual differences in human livers
    LIFE SCIENCES
    
    G.J. Hammons et al., "Specific site methylation in the 5 '-flanking region of CYP1A2 - Interindividual differences in human livers", LIFE SCI, 69(7), 2001, pp. 839-845
39. Groeneveld, GJ; van Kan, HJM; Torano, JS; Veldink, JH; Guchelaar, HJ; Wokke, JHJ; van den Berg, LH
    Inter- and intraindividual variability of riluzole serum concentrations inpatients with ALS
    JOURNAL OF THE NEUROLOGICAL SCIENCES
    
    G.J. Groeneveld et al., "Inter- and intraindividual variability of riluzole serum concentrations inpatients with ALS", J NEUR SCI, 191(1-2), 2001, pp. 121-125
40. Court, MH; Duan, SX; Von Moltke, LL; Greenblatt, DJ; Patten, CJ; Miners, JO; Mackenzie, PI
    Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    M.H. Court et al., "Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms", J PHARM EXP, 299(3), 2001, pp. 998-1006
41. Zhu, B; Ou-Yang, DS; Chen, XP; Huang, SL; Tan, ZR; He, N; Zhou, HH
    Assessment of cytochrome P450 activity by a five-drug cocktail approach
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    B. Zhu et al., "Assessment of cytochrome P450 activity by a five-drug cocktail approach", CLIN PHARM, 70(5), 2001, pp. 455-461
42. Tsutsumi, K; Kotegawa, T; Matsuki, S; Tanaka, Y; Ishii, Y; Kodama, Y; Kuranari, M; Miyakawa, I; Nakano, S
    The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    K. Tsutsumi et al., "The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans", CLIN PHARM, 70(2), 2001, pp. 121-125
43. Hartter, S; Ursing, C; Morita, S; Tybring, G; von Bahr, C; Christensen, M; Rojdmark, S; Bertilsson, L
    Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    S. Hartter et al., "Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study", CLIN PHARM, 70(1), 2001, pp. 10-16
44. Kusumoto, M; Ueno, K; Oda, A; Takeda, K; Mashimo, K; Takaya, K; Fujimura, Y; Nishihori, T; Tanaka, K
    Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    M. Kusumoto et al., "Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men", CLIN PHARM, 69(3), 2001, pp. 104-107
45. Tantcheva-Poor, I; Servera-Llaneras, M; Scharffetter-Kochanek, K; Fuhr, U
    Liver cytochrome P450CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients
    BRITISH JOURNAL OF DERMATOLOGY
    
    I. Tantcheva-Poor et al., "Liver cytochrome P450CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients", BR J DERM, 144(6), 2001, pp. 1127-1132
46. Baker, JR; Satarug, S; Reilly, PEB; Edwards, RJ; Ariyoshi, N; Kamataki, T; Moore, MR; Williams, DJ
    Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples
    BIOCHEMICAL PHARMACOLOGY
    
    J.R. Baker et al., "Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples", BIOCH PHARM, 62(6), 2001, pp. 713-721
47. Zaccaro, C; Sweitzer, S; Pipino, S; Gorman, N; Sinclair, PR; Sinclair, JF; Nebert, DW; De Matteis, F
    Role of cytochrome P450 1A2 in bilirubin degradation - Studies in Cyp1a2 (-/-) mutant mice
    BIOCHEMICAL PHARMACOLOGY
    
    C. Zaccaro et al., "Role of cytochrome P450 1A2 in bilirubin degradation - Studies in Cyp1a2 (-/-) mutant mice", BIOCH PHARM, 61(7), 2001, pp. 843-849
48. Long, L; Moschel, RC; Dolan, ME
    Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism
    BIOCHEMICAL PHARMACOLOGY
    
    L. Long et al., "Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism", BIOCH PHARM, 61(6), 2001, pp. 721-726
49. Sugihara, K; Kitamura, S; Yamada, T; Ohta, S; Yamashita, K; Yasuda, M; Fujii-Kuriyama, Y
    Aryl hydrocarbon receptor (AhR)-mediated induction of xanthine oxidase/xanthine dehydrogenase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    K. Sugihara et al., "Aryl hydrocarbon receptor (AhR)-mediated induction of xanthine oxidase/xanthine dehydrogenase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin", BIOC BIOP R, 281(5), 2001, pp. 1093-1099
50. Liu, N; Zhang, QY; Vakharia, D; Dunbar, D; Kaminsky, LS
    Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 orCYP1A2?
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    N. Liu et al., "Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 orCYP1A2?", ARCH BIOCH, 389(1), 2001, pp. 130-134
51. Aoki, J; Sato, M; Itakura, T
    An eel cytochrome P450 1A gene having no XRE sequences in its 5 ' upstreamregion of 1600 bp
    MARINE BIOTECHNOLOGY
    
    J. Aoki et al., "An eel cytochrome P450 1A gene having no XRE sequences in its 5 ' upstreamregion of 1600 bp", MAR BIOTEC, 2(2), 2000, pp. 167-172
52. MacLeod, SL; Nowell, S; Massengill, J; Jazieh, A; McClure, G; Plaxco, J; Kadlubar, FF; Lang, NP
    Cancer therapy and polymorphisms of cytochromes P450
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    
    S.L. MacLeod et al., "Cancer therapy and polymorphisms of cytochromes P450", CLIN CH L M, 38(9), 2000, pp. 883-887
53. Basile, VS; Ozdemir, V; Masellis, M; Walker, ML; Heltzer, HY; Lieberman, JA; Potkin, SG; Alva, G; Kalow, W; Macciardi, FM; Kennedy, JL
    A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia
    MOLECULAR PSYCHIATRY
    
    V.S. Basile et al., "A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia", MOL PSYCHI, 5(4), 2000, pp. 410-417
54. Hurst, CH; DeVito, MJ; Birnbaum, LS
    Tissue disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in maternal and developing Long-Evans rats following subchronic exposure
    TOXICOLOGICAL SCIENCES
    
    C.H. Hurst et al., "Tissue disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in maternal and developing Long-Evans rats following subchronic exposure", TOXICOL SCI, 57(2), 2000, pp. 275-283
55. Hurst, CH; DeVito, MJ; Setzer, RW; Birnbaum, LS
    Acute administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in pregnant Long Evans rats: Association of measured tissue concentrations with developmental effects
    TOXICOLOGICAL SCIENCES
    
    C.H. Hurst et al., "Acute administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in pregnant Long Evans rats: Association of measured tissue concentrations with developmental effects", TOXICOL SCI, 53(2), 2000, pp. 411-420
56. Aitchison, KJ; Gonzalez, FJ; Quattrochi, LC; Sapone, A; Zhao, JH; Zaher, H; Elizondo, G; Bryant, C; Munro, J; Collier, DA; Makoff, AJ; Kerwin, RW
    Identification of novel polymorphisms in the 5 ' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance
    PHARMACOGENETICS
    
    K.J. Aitchison et al., "Identification of novel polymorphisms in the 5 ' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance", PHARMACOGEN, 10(8), 2000, pp. 695-704
57. Rettie, AE; Lang, DH
    Can caffeine metabolism be used as an in-vivo probe for human flavin-containing monooxygenase activity?
    PHARMACOGENETICS
    
    A.E. Rettie e D.H. Lang, "Can caffeine metabolism be used as an in-vivo probe for human flavin-containing monooxygenase activity?", PHARMACOGEN, 10(3), 2000, pp. 275-277
58. Zaigler, M; Rietbrock, S; Szymanski, J; Dericks-Tan, JSE; Staib, AH; Fuhr, U
    Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    M. Zaigler et al., "Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women", INT J CL PH, 38(5), 2000, pp. 235-244
59. Bechtel, YC; Haffen, E; Lelouet, H; Brientini, MP; Paintaud, G; Miguet, JP; Bechtel, PR
    Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    Y.C. Bechtel et al., "Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients", INT J CL PH, 38(10), 2000, pp. 467-475
60. Zaigler, M; Tantcheva-Poor, I; Fuhr, U
    Problems and perspectives of phenotyping for drug-metabolizing enzymes in man
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    M. Zaigler et al., "Problems and perspectives of phenotyping for drug-metabolizing enzymes in man", INT J CL PH, 38(1), 2000, pp. 1-9
61. Thatcher, NJ; Edwards, RJ; Lemoine, NR; Doehmer, J; Davies, DS
    The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy
    CANCER GENE THERAPY
    
    N.J. Thatcher et al., "The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy", CANC GENE T, 7(4), 2000, pp. 521-525
62. Cui, L; Takahashi, S; Tada, M; Kato, K; Yamada, Y; Kohri, K; Shirai, T
    Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: Resultswith 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2 '-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity
    JAPANESE JOURNAL OF CANCER RESEARCH
    
    L. Cui et al., "Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: Resultswith 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2 '-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity", JPN J CANC, 91(1), 2000, pp. 52-58
63. Aryal, P; Terashita, T; Guengerich, FP; Shimada, T; Oda, Y
    Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-Cytochrome P450 reductase andbacterial O-acetyltransferase in SOS/umu assay
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
    
    P. Aryal et al., "Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-Cytochrome P450 reductase andbacterial O-acetyltransferase in SOS/umu assay", ENV MOL MUT, 36(2), 2000, pp. 121-126
64. Sindhu, RK; Sakai, H; Kikkawa, Y
    Effect of hyperoxia on rat pulmonary and hepatic cytochrome P450 monooxygenases
    ARCHIVES OF TOXICOLOGY
    
    R.K. Sindhu et al., "Effect of hyperoxia on rat pulmonary and hepatic cytochrome P450 monooxygenases", ARCH TOXIC, 73(10-11), 2000, pp. 540-546
65. Carrillo, JA; Benitez, J
    Clinically significant pharmacokinetic interactions between dietary caffeine and medications
    CLINICAL PHARMACOKINETICS
    
    J.A. Carrillo e J. Benitez, "Clinically significant pharmacokinetic interactions between dietary caffeine and medications", CLIN PHARMA, 39(2), 2000, pp. 127-153
66. Welfare, MR; Bassendine, MF; Daly, AK
    The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    M.R. Welfare et al., "The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects", BR J CL PH, 49(3), 2000, pp. 240-243
67. Hagg, S; Spigset, O; Mjorndal, T; Dahlqvist, R
    Effect of caffeine on clozapine pharmacokinetics in healthy volunteers
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    S. Hagg et al., "Effect of caffeine on clozapine pharmacokinetics in healthy volunteers", BR J CL PH, 49(1), 2000, pp. 59-63
68. Jorritsma, U; Schrader, E; Klaunick, G; Kapitulnik, J; Hirsch-Ernst, KI; Kahl, GF; Foth, H
    Monitoring of cytochrome P-450 1A activity by determination of the urinarypattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats
    TOXICOLOGY
    
    U. Jorritsma et al., "Monitoring of cytochrome P-450 1A activity by determination of the urinarypattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats", TOXICOLOGY, 144(1-3), 2000, pp. 229-236
69. Aitchison, KJ; Jann, MW; Zhao, JH; Sakai, T; Zaher, H; Wolff, K; Collier, DA; Kerwin, RW; Gonzalez, FJ
    Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice
    JOURNAL OF PSYCHOPHARMACOLOGY
    
    K.J. Aitchison et al., "Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice", J PSYCHOPH, 14(4), 2000, pp. 353-359
70. Han, XM; Zhou, HH
    Polymorphism of CYP450 and cancer susceptibility
    ACTA PHARMACOLOGICA SINICA
    
    X.M. Han e H.H. Zhou, "Polymorphism of CYP450 and cancer susceptibility", ACT PHAR SI, 21(8), 2000, pp. 673-679
71. Cheng, ZN; Zhou, HH
    Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis
    ACTA PHARMACOLOGICA SINICA
    
    Z.N. Cheng e H.H. Zhou, "Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis", ACT PHAR SI, 21(7), 2000, pp. 587-590
72. Carrillo, JA; Christensen, M; Ramos, SI; Alm, C; Dahl, ML; Benitez, J; Bertilsson, L
    Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine
    THERAPEUTIC DRUG MONITORING
    
    J.A. Carrillo et al., "Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine", THER DRUG M, 22(4), 2000, pp. 409-417
73. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Ono, S; Kaneko, S; Otani, K; Inoue, Y
    Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
    THERAPEUTIC DRUG MONITORING
    
    K. Mihara et al., "Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia", THER DRUG M, 22(3), 2000, pp. 245-249
74. Eap, CB; Bender, S; Gastpar, M; Fischer, W; Haarmann, C; Powell, K; Jonzier-Perey, M; Cochard, N; Baumann, P
    Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients
    THERAPEUTIC DRUG MONITORING
    
    C.B. Eap et al., "Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients", THER DRUG M, 22(2), 2000, pp. 209-214
75. Moller, SE; Larsen, F; Pitsiu, M; Rolan, PE
    Effect of citalopram on plasma levels of oral theophylline
    CLINICAL THERAPEUTICS
    
    S.E. Moller et al., "Effect of citalopram on plasma levels of oral theophylline", CLIN THER, 22(12), 2000, pp. 1494-1501
76. Williams, JA; Martin, FL; Muir, GH; Hewer, A; Grover, PL; Phillips, DH
    Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue
    CARCINOGENESIS
    
    J.A. Williams et al., "Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue", CARCINOGENE, 21(9), 2000, pp. 1683-1689
77. Lampe, JW; King, IB; Li, S; Grate, MT; Barale, KV; Chen, C; Feng, ZD; Potter, JD
    Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets
    CARCINOGENESIS
    
    J.W. Lampe et al., "Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets", CARCINOGENE, 21(6), 2000, pp. 1157-1162
78. Komatsu, T; Yamazaki, H; Shimada, N; Nakajima, M; Yokoi, T
    Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes
    DRUG METABOLISM AND DISPOSITION
    
    T. Komatsu et al., "Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes", DRUG META D, 28(12), 2000, pp. 1457-1463
79. Ng, CY; Ghabrial, H; Morgan, DJ; Ching, MS; Smallwood, RA; Angus, PW
    Impaired elimination of propranolol due to right heart failure: Drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity
    DRUG METABOLISM AND DISPOSITION
    
    C.Y. Ng et al., "Impaired elimination of propranolol due to right heart failure: Drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity", DRUG META D, 28(10), 2000, pp. 1217-1221
80. Sinclair, PR; Gorman, N; Walton, HS; Bement, WJ; Dalton, TP; Sinclair, JF; Smith, AG; Nebert, DW
    CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene andiron
    TOXICOLOGY AND APPLIED PHARMACOLOGY
    
    P.R. Sinclair et al., "CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene andiron", TOX APPL PH, 162(1), 2000, pp. 60-67
81. Janus, K; Antoszek, J
    The effect of sex and age on caffeine pharmacokinetics in cattle
    RESEARCH IN VETERINARY SCIENCE
    
    K. Janus e J. Antoszek, "The effect of sex and age on caffeine pharmacokinetics in cattle", RES VET SCI, 69(1), 2000, pp. 33-37
82. Brockmoller, J; Cascorbi, I; Henning, S; Meisel, C; Roots, I
    Molecular genetics of cancer susceptibility
    PHARMACOLOGY
    
    J. Brockmoller et al., "Molecular genetics of cancer susceptibility", PHARMACOL, 61(3), 2000, pp. 212-227
83. Raaska, K; Neuvonen, PJ
    Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    K. Raaska e P.J. Neuvonen, "Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia", EUR J CL PH, 56(8), 2000, pp. 585-589
84. Sindhu, RK; Mitsuhashi, M; Kikkawa, Y
    Induction of cytochrome P-450 1A2 by oxidized tryptophan in Hepa lclc7 cells
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    R.K. Sindhu et al., "Induction of cytochrome P-450 1A2 by oxidized tryptophan in Hepa lclc7 cells", J PHARM EXP, 292(3), 2000, pp. 1008-1014
85. Ueno, T; Tamura, S; Frels, WI; Shou, M; Gonzalez, FJ; Kimura, S
    A transgenic mouse expressing human CYP1A2 in the pancreas
    BIOCHEMICAL PHARMACOLOGY
    
    T. Ueno et al., "A transgenic mouse expressing human CYP1A2 in the pancreas", BIOCH PHARM, 60(6), 2000, pp. 857-863
86. Dertinger, SD; Lantum, HBM; Silverstone, AE; Gasiewicz, TA
    Effect of 3 '-methoxy-4 '-nitroflavone on benzo[a]pyrene toxicity - Aryl hydrocarbon receptor-dependent and -independent mechanisms
    BIOCHEMICAL PHARMACOLOGY
    
    S.D. Dertinger et al., "Effect of 3 '-methoxy-4 '-nitroflavone on benzo[a]pyrene toxicity - Aryl hydrocarbon receptor-dependent and -independent mechanisms", BIOCH PHARM, 60(2), 2000, pp. 189-196
87. Longo, V; Ingelman-Sundberg, M; Amato, G; Salvetti, A; Gervasi, PG
    Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa
    BIOCHEMICAL PHARMACOLOGY
    
    V. Longo et al., "Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa", BIOCH PHARM, 59(11), 2000, pp. 1425-1432
88. Davydov, DR; Petushkova, NA; Archakov, AI; Hoa, GHB
    Stabilization of P4502B4 by its association with P450 1A2 revealed by high-pressure spectroscopy
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    D.R. Davydov et al., "Stabilization of P4502B4 by its association with P450 1A2 revealed by high-pressure spectroscopy", BIOC BIOP R, 276(3), 2000, pp. 1005-1012
89. Lekas, P; Tin, KL; Lee, C; Prokipcak, RD
    The human cytochrome P450 1A1 mRNA is rapidly degraded in HepG2 cells
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    P. Lekas et al., "The human cytochrome P450 1A1 mRNA is rapidly degraded in HepG2 cells", ARCH BIOCH, 384(2), 2000, pp. 311-318
90. Sinclair, PR; Gorman, N; Walton, HS; Bement, WJ; Szakacs, J; Gonzalez, FJ; Dalton, TP; Nebert, DW; Sinclair, JF
    Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    P.R. Sinclair et al., "Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone", ARCH BIOCH, 384(2), 2000, pp. 383-390
91. Hudecek, J; Anzenbacherova, E; Anzenbacher, P; Munro, AW; Hildebrandt, P
    Structural similarities and differences of the heme pockets of various P450 isoforms as revealed by resonance Raman spectroscopy
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    J. Hudecek et al., "Structural similarities and differences of the heme pockets of various P450 isoforms as revealed by resonance Raman spectroscopy", ARCH BIOCH, 383(1), 2000, pp. 70-78
92. Hayashi, K; Sakaki, T; Kominami, S; Inouye, K; Yabusaki, Y
    Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b(5) in yeast
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    K. Hayashi et al., "Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b(5) in yeast", ARCH BIOCH, 381(1), 2000, pp. 164-170
93. Shih, H; Pickwell, GV; Quattrochi, LC
    Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    H. Shih et al., "Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer", ARCH BIOCH, 373(1), 2000, pp. 287-294
94. Jokinen, MJ; Ahonen, J; Neuvonen, PJ; Olkkola, KT
    The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine
    ANESTHESIA AND ANALGESIA
    
    M.J. Jokinen et al., "The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine", ANESTH ANAL, 91(5), 2000, pp. 1207-1212
95. Bulun, SE; Zeitoun, KM; Kilic, G
    Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
    
    S.E. Bulun et al., "Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues", AM J OBST G, 182(4), 2000, pp. 767-775
96. Koide, A; Fuwa, K; Furukawa, F; Hirose, M; Nishikawa, A; Mori, Y
    Effect of cigarette smoke on the mutagenic activation of environmental carcinogens by rodent liver
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    
    A. Koide et al., "Effect of cigarette smoke on the mutagenic activation of environmental carcinogens by rodent liver", MUT RES-F M, 428(1-2), 1999, pp. 165-176
97. Kranendonk, M; Fisher, CW; Roda, R; Carreira, F; Theisen, P; Laires, A; Rueff, J; Vermeulen, NPE; Estabrook, RW
    Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: Comparison of three types of expression systems
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
    
    M. Kranendonk et al., "Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: Comparison of three types of expression systems", MUT RES-GTE, 439(2), 1999, pp. 287-300
98. Bu-Abbas, A; Clifford, MN; Walker, R; Ioannides, C
    Modulation of hepatic cytochrome P450 activity and carcinogen bioactivation by black and decaffeinated black tea
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
    
    A. Bu-Abbas et al., "Modulation of hepatic cytochrome P450 activity and carcinogen bioactivation by black and decaffeinated black tea", ENV TOX PH, 7(1), 1999, pp. 41-47
99. Murray, M
    Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (Review)
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    
    M. Murray, "Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (Review)", INT J MOL M, 3(3), 1999, pp. 227-238
100. Peters, JM; Morishima, H; Ward, JH; Coakley, CJ; Kimura, S; Gonzalez, FJ
     Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice
     TOXICOLOGICAL SCIENCES
     
     J.M. Peters et al., "Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice", TOXICOL SCI, 50(1), 1999, pp. 82-89